Repligen Corporation (NASDAQ:RGEN) Receives $166.43 Consensus Target Price from Brokerages

Repligen Corporation (NASDAQ:RGEN) has been assigned an average recommendation of “Buy” from the eighteen brokerages that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and three have given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $166.4286.

Several equities research analysts recently issued reports on RGEN shares. HSBC dropped their price target on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Wells Fargo & Company boosted their target price on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 13th. Royal Bank Of Canada assumed coverage on shares of Repligen in a research report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target on the stock. Finally, JPMorgan Chase & Co. lifted their price target on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th.

Insider Transactions at Repligen

In other Repligen news, CFO Jason Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Repligen

Institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System lifted its holdings in shares of Repligen by 13,158.5% in the 2nd quarter. California State Teachers Retirement System now owns 8,201,681 shares of the biotechnology company’s stock worth $1,119,037,000 after purchasing an additional 8,139,821 shares during the last quarter. United Capital Financial Advisors LLC bought a new position in Repligen during the 2nd quarter worth $380,756,000. Opti Capital Management LP bought a new position in Repligen during the 4th quarter worth $2,399,209,000. Maverick Capital Ltd. acquired a new stake in Repligen in the first quarter worth $178,946,000. Finally, Wasatch Advisors LP acquired a new stake in Repligen in the first quarter worth $146,513,000. 97.64% of the stock is owned by institutional investors.

Repligen Price Performance

RGEN opened at $168.53 on Friday. The company has a market capitalization of $9.51 billion, a P/E ratio of 230.86, a PEG ratio of 3.06 and a beta of 1.05. The company has a 50-day moving average of $156.80 and a 200-day moving average of $134.68. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. Repligen has a 1-year low of $100.99 and a 1-year high of $188.73.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same period last year, the firm earned $0.26 earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts expect that Repligen will post 2.06 EPS for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.